Bath Savings Trust Co Grows Stock Holdings in Veeva Systems Inc. $VEEV

Bath Savings Trust Co lifted its position in shares of Veeva Systems Inc. (NYSE:VEEV) by 10.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,886 shares of the technology company’s stock after acquiring an additional 3,965 shares during the quarter. Veeva Systems accounts for about 1.2% of Bath Savings Trust Co’s holdings, making the stock its 23rd biggest position. Bath Savings Trust Co’s holdings in Veeva Systems were worth $12,478,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of Veeva Systems in the second quarter valued at approximately $384,265,000. Durable Capital Partners LP purchased a new position in Veeva Systems during the second quarter worth about $281,351,000. AQR Capital Management LLC boosted its position in shares of Veeva Systems by 111.7% in the second quarter. AQR Capital Management LLC now owns 1,838,046 shares of the technology company’s stock worth $526,508,000 after acquiring an additional 969,905 shares during the last quarter. Schroder Investment Management Group boosted its holdings in shares of Veeva Systems by 1,039.4% in the 2nd quarter. Schroder Investment Management Group now owns 1,014,974 shares of the technology company’s stock valued at $292,292,000 after purchasing an additional 925,896 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Veeva Systems by 20.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock valued at $924,754,000 after acquiring an additional 689,700 shares during the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

VEEV has been the topic of a number of recent research reports. Truist Financial lifted their price target on shares of Veeva Systems from $268.00 to $275.00 and gave the company a “hold” rating in a research report on Thursday, August 28th. Mizuho increased their price target on Veeva Systems from $295.00 to $325.00 and gave the company an “outperform” rating in a report on Friday, August 29th. Weiss Ratings reissued a “buy (b-)” rating on shares of Veeva Systems in a research report on Monday. Canaccord Genuity Group reiterated a “buy” rating on shares of Veeva Systems in a research report on Tuesday, November 25th. Finally, JPMorgan Chase & Co. raised shares of Veeva Systems from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $290.00 to $330.00 in a research report on Monday, September 8th. Eighteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $307.42.

Insiders Place Their Bets

In other Veeva Systems news, SVP Jonathan Faddis sold 14,595 shares of the company’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $300.00, for a total transaction of $4,378,500.00. Following the completion of the sale, the senior vice president directly owned 8,588 shares of the company’s stock, valued at approximately $2,576,400. This represents a 62.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the completion of the sale, the insider owned 25,325 shares of the company’s stock, valued at approximately $7,765,151.50. This trade represents a 19.15% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 24,665 shares of company stock worth $7,438,000. 10.30% of the stock is owned by insiders.

Veeva Systems Price Performance

NYSE VEEV opened at $217.70 on Friday. Veeva Systems Inc. has a 12 month low of $201.54 and a 12 month high of $310.50. The firm has a market capitalization of $35.78 billion, a PE ratio of 42.35, a P/E/G ratio of 1.60 and a beta of 1.05. The company’s 50 day simple moving average is $266.77 and its 200 day simple moving average is $277.30.

Veeva Systems (NYSE:VEEV) last announced its quarterly earnings data on Thursday, November 20th. The technology company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.09. Veeva Systems had a return on equity of 13.68% and a net margin of 27.93%.The business had revenue of $0.81 million during the quarter, compared to analyst estimates of $792.37 million. During the same quarter in the prior year, the firm posted $1.75 earnings per share. The company’s revenue was up 16.0% on a year-over-year basis. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. Sell-side analysts anticipate that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.